The Citizens Commission on Human Rights (CCHR) today urged consumers to read psychotropic prescription drug labeling for warnings about suicide, aggression, and homicidal ideation, and to demand that prescribing physicians explain these risks, even when they are listed as rare. The call follows news reports of violent crimes in which individuals were reportedly taking or withdrawing from prescribed antidepressants, stimulants, or other psychiatric drugs with documented side effects of aggression, homicidal and suicidal ideation. CCHR says such reports highlight a broader issue: patients should be fully aware of potential risks disclosed by regulators and manufacturers, and prescribers should ensure they are informed.
CCHR's decades-long campaign has drawn attention to reports of agitation, aggression, suicidal behavior, and homicidal thoughts associated with some psychotropic drugs. U.S. and foreign regulators have subsequently required warnings or adverse-reaction information in the labeling of various psychiatric drugs. Jan Eastgate, president of CCHR International, stated, "A rare warning buried in a package insert is not the same as a doctor explaining the risk to a patient. Listing a side effect as 'rare' does not establish that the patient was told about it, understood it, or agreed to take that risk. Meaningful informed consent requires meaningful disclosure and prescriber accountability."
The question of a psychiatrist's responsibility is being debated in courtrooms and within the profession. Psychiatric Times recently published "Psychiatry on Trial: Are Psychiatrists Responsible for Their Patients' Criminal Behavior?" Discussing a high-profile murder case where the defense argued that psychiatric polypharmacy contributed to violent behavior, the journal noted that "a good portion of the public and the media appear to support the defense theory" and that the litigation "places psychiatrists and other mental health providers under scrutiny." The authors concluded that "psychiatry itself may end up on trial."
When prescribed drugs are alleged to have induced violent or criminal behavior, one legal doctrine is involuntary intoxication. Its applicability depends on the facts and governing law, including whether the drug was taken as prescribed and whether the person knew or reasonably could have known of the particular intoxicating or behavioral effect. Eastgate added, "A judge allowing a jury to hear evidence about prescription drugs is not the same as a physician warning a patient before the first dose. The existence of a warning in drug labeling does not, by itself, establish that an individual patient was adequately informed. Psychiatrists must disclose what patients need to make informed decisions."
The issue is not new. In a December 2005 article on psychopharmacology liability, Psychiatric Times discussed psychiatrists' professional duties in the context of the FDA's 2004 public health advisory on antidepressants. That advisory identified reports of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (severe restlessness), hypomania, and mania in adults and children. In October 2004, the FDA directed manufacturers to add a boxed warning concerning suicidality in children and adolescents; the warning was later expanded to young adults.
CCHR's compilation of international regulatory agency warnings identifies 57 warnings or safety notices since 2004 involving violence, aggression, or hostility, compared with five in 2004—a 1,040% increase. Thirteen of those notices specifically reference homicidal ideation or thoughts of harming others. Drug labeling provides specific examples. Homicidal ideation was added to labeling for extended-release venlafaxine in 2005. In 2009, the FDA required a boxed neuropsychiatric warning for bupropion products, citing postmarketing reports including hostility, agitation, aggression, psychosis, homicidal ideation, and suicidal events. In 2023, the FDA required class-wide labeling for Central Nervous System stimulants stating that "anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation" have been observed with stimulant abuse and/or misuse. Esketamine nasal spray labeling instructs patients to seek medical attention for new or sudden changes in mood, behavior, thoughts, or feelings, including acting aggressive, angry, or violent. The antipsychotic aripiprazole lists homicidal ideation among rare adverse reactions in adults.
For CCHR, the central issue is what happens after such risks appear in official labeling. Printing a warning does not ensure that a patient has seen it, understood it, or discussed it with a physician. That concern has also entered public policy. A 2026 Tennessee law requires toxicology testing for psychiatric and other drugs following specified violent incidents. CCHR has called for the law to be enacted in every state.
Eastgate concluded, "Drug labeling now contains warnings and adverse-event information that consumers have a right to know about. While not all individuals taking a prescription psychotropic drug will become violent or suicidal, they should read these warnings and ask questions before agreeing to treatment. Prescribers should explain potentially serious violent and suicidal adverse effects—including those considered rare—and document that the patient was given the information necessary to make an informed decision. A label alone does not ensure informed consent."
Ultimately, CCHR says the issue is not whether every patient will experience these reactions, but whether patients are adequately informed when regulators and manufacturers have identified potentially serious behavioral adverse effects—and whether prescribers are held accountable for ensuring that patients are warned about those risks. Consumers should be able to weigh risks, recognize warning signs should they emerge, and seek prompt medical advice about concerning changes. Patients should not abruptly stop taking psychiatric drugs; any reduction or discontinuation should be undertaken with appropriate medical supervision.
